A letter submitted on behalf of the Digital Medicine Society (DiMe) for consideration by the U.S. Food and Drug Administration (FDA) regarding Docket No. FDA-2021-D-0789 for “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability.”
June 2022